Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, Pediatric Division, University of Verona, 37134 Verona, Italy.
Institute of Translational Pharmacology, National Research Council, 90146 Palermo, Italy.
Genes (Basel). 2022 Mar 28;13(4):599. doi: 10.3390/genes13040599.
Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, along with patient pheno-endotypization, will increase our knowledge of several molecular mechanisms involved in asthma pathophysiology and contribute to selecting and stratifying appropriate treatment for each patient.
个体化医学是一种针对个体特征进行干预以最大化健康结果的医疗方法,正在迅速成为许多疾病的现实。儿童哮喘是一种异质性疾病,许多儿童的症状无法得到控制。因此,需要采取个体化方法来改善儿童哮喘的结局。基因组学和药物基因组学等快速发展的领域可能为实现儿童哮喘的控制和降低未来风险提供一种途径。特别是,药物基因组学可以为识别新型分子机制和生物标志物以指导治疗提供工具。新兴的高通量技术以及患者表型-基因型分析将增加我们对哮喘病理生理学中涉及的几个分子机制的了解,并有助于为每个患者选择和分层适当的治疗方法。